Cencora, Inc. (NYSE:COR) Shares Purchased by Pacer Advisors Inc.

Pacer Advisors Inc. raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 6.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,204,242 shares of the company’s stock after acquiring an additional 138,868 shares during the period. Cencora makes up 1.1% of Pacer Advisors Inc.’s holdings, making the stock its 18th largest position. Pacer Advisors Inc. owned approximately 1.14% of Cencora worth $495,249,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Lake Street Advisors Group LLC lifted its holdings in Cencora by 1.3% in the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock worth $769,000 after purchasing an additional 43 shares during the period. Venturi Wealth Management LLC raised its position in shares of Cencora by 1.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock worth $1,001,000 after buying an additional 46 shares in the last quarter. Prime Capital Investment Advisors LLC lifted its stake in shares of Cencora by 1.2% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock worth $848,000 after acquiring an additional 46 shares during the period. J.W. Cole Advisors Inc. boosted its holdings in shares of Cencora by 1.3% in the third quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock valued at $826,000 after acquiring an additional 48 shares in the last quarter. Finally, Impact Partnership Wealth LLC increased its stake in shares of Cencora by 2.6% during the third quarter. Impact Partnership Wealth LLC now owns 2,042 shares of the company’s stock valued at $460,000 after acquiring an additional 51 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

Cencora stock opened at $248.45 on Monday. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. The firm’s 50 day simple moving average is $237.51 and its 200-day simple moving average is $234.83. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company has a market cap of $48.02 billion, a P/E ratio of 33.08, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date was Friday, November 15th. Cencora’s payout ratio is 29.29%.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock worth $17,790,912 over the last quarter. Corporate insiders own 15.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on COR. Leerink Partners decreased their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Wells Fargo & Company cut their price objective on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday. Evercore ISI upped their price target on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, UBS Group lifted their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $277.00.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.